CD166 Mesenchymal marker characterizes ADMPC for Periodontal transplant.

Ancell CD166/FITC used as a Mesenchymal marker to characterize Adipose Tissue-Derived Multilineage Progenitor cells (ADMPC) used for Periodontal transplant. The results of this study suggest tha autologous ADMPC transplantation may be a good option for treatment of severe periodontitis. “Periodontal Regeneration by Allogeneic Transplantation of Adipose Tissue Derived Multi-Lineage Progenitor Stem Cells in vivo.“ M […]

CD166 Mesenchymal marker characterizes ADMPC for Periodontal transplant. Read More »

Glioma treatment using Checkpoint inhibition + CAR looks promising!

CD133 specific CAR-macrophages created in situ using NanoPorter hydrogel in combination with CD47 checkpoint blocking antibody improves post operative Glioblastoma survival in a humanized mouse model “Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy” Chen Chen, Xinyi Jiang, et al. Science Translational Medicine 14: 656 DOI: 10.1126/scitranslmed.abn1128 CD47

Glioma treatment using Checkpoint inhibition + CAR looks promising! Read More »

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance

Siglecs and their ligands are expressed by many tumors, and can serve to down-regulate immune response. REVIEW article: “The intriguing roles of Siglec family members in the tumor microenvironment” Kui-Ying Jiang, Ling Wang, et al. (2022) Biomarker Research 10: 22 PMID: 35418152 “Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10” Shan-Shan Yin, Feng-Hou Gao

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance Read More »

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”?

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors. Link to Medical News Today Article Link to Clinical Trial Link to a Background article Ancell human PD-1 related Research Products CD279(PD-1) CD274 (PD-L1) CD273 (PD-L2)

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”? Read More »

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety

“Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies” Natasha Helleberg Madsen, Monika Gad, Jesper Larsen. (Feb 5, 2022) J Immunol Methods 502: 113231. https://doi.org/10.10 PBMC were stimulated with immobilized ANC28.1, CD28.1 and muromonab CD3. Assessed Cytokines and levels of Activation molecules by flow could determine the

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety Read More »

Ancell reagents and personnel involved in a new SARS-Co-V2 breast milk antibody study

“Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Breast Milk from Lactating Women Following the COVID-19 Booster Vaccination” Andrea M Henle MedRxiv (Feb 24, 2022 Pre print) doi: https://doi.org/10.1101/2022.02.23.22271414 Related Ancell products: anti-human IgA monoclonal antibody anti-human IgG monoclonal antibody Recombinant SARS-CO-V2-RBD-His protein #581-820 (Inquire)

Ancell reagents and personnel involved in a new SARS-Co-V2 breast milk antibody study Read More »

Exosomes increase PD-L1 expression and induce tolerance to NIMA

A University of WI Madison research group used Ancell antibodies to analyze exosomes involved in the induction of tolerance to non-inherited maternal antigens(NIMA). This could have implications for allogeneic graft tolerance./ “Cross-Decoration of Dendritic Cells by Non-Inherited Maternal Antigen-Containing Extracellular Vesicles: Potential Mechanism for PD-L1-Based Tolerance in Cord Blood and Organ Transplantation”Diego A. Lema, A

Exosomes increase PD-L1 expression and induce tolerance to NIMA Read More »

Ancell anti-CD63 antibody used to capture Tumor Extracellular Vesicles from Colorectal Cancer patient plasma in a high throughput device

The device captures EV from plasma and analyzes clinically relevant tumour biomarkers (EGFR, EpCAM, CD24 and GPA33) of colorectal cancer (CRC). The results were predictive of disease severity and prognosis for the test subjects. “An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma” Jongmin Park, Hakho Lee, et al.

Ancell anti-CD63 antibody used to capture Tumor Extracellular Vesicles from Colorectal Cancer patient plasma in a high throughput device Read More »